OBR Daily Commentary

forumImage

AZ’ Imfinzi Fails In Head And Neck Cancer Trial

(PharmaTimes [UK]) Dec 7, 2018 - AstraZeneca and MedImmune’s Imfinzi has failed to hit targets in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The Phase III EAGLE trial assessed Imfinzi (durvalumab) monotherapy or Imfinzi in combination with tremelimumab, an anti-CTLA4 antibody, versus standard-of-care (SoC) chemotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who experienced disease progression following platinum-based chemotherapy, regardless of their PD-L1 tumour status.

Read Article arrow

Howard S. Hochster, MD (Posted: December 08, 2018)

quotesOnce again, despite our hopes, and the imagination of the public, that a magic-bullet immunotherapy will work globally, we see the limitations of the IO approach. We justify possible activity on the basis of smoking-induced cancers or viral-induced, yet these cancers (like many solid tumors) are not melanoma. The era of continuing to throw anti-PD(L)1 and anti-CTLA4 agents against the wall and seeing what sticks needs to end. Let’s be smarter and try to select the appropriate patients using predictive markers!quotes

Add Comment 1 Comment
forumImage

Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrates Clinical Activity in Previously Treated Patients with dMMR or MSI-H Metastatic Colorectal Cancer

(Morningstar) Jan 20, 2018 - Bristol-Myers Squibb Company today announced new data from a cohort of the phase 2 CheckMate -142 trial evaluating Opdivo (nivolumab) and Yervoy (ipilimumab) for the treatment of patients with DNA mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC).

Read Article arrow

Howard S. Hochster, MD (Posted: January 22, 2018)

quotesGreat work by Mike Overman and colleagues showing prolonged benefit to Nivo (3 mg,kg) and Ipi (1 mg,kg) given x 4 doses. Median duration of response not yet reached and over one year. This does suggest the combo is more active than single agent Nivo. But randomized trials are needed in this rare MSI-high population. Now possible in the NRG/SWOG COMMIT trial available on CTSU. Please screen your patients early and consider this for first line therapy. After all, MSI-high patients have great responses to chemo also. Order may matter.quotes

Add Comment 1 Comment
forumImage

First-Time Data for Merck’s KEYTRUDA® (pembrolizumab) in Patients with Previously Treated Advanced Hepatocellular Carcinoma (HCC) to be Presented at 2018 ASCO GI Symposium

(Merck) Jan 19, 2018 - Merck, known as MSD outside the United States and Canada, today announced findings from the registrational phase 2 KEYNOTE-224 trial investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in patients with advanced hepatocellular carcinoma (HCC), the most common type of liver cancer, who were previously treated with systemic therapy (sorafenib).

Read Article arrow

Howard S. Hochster, MD (Posted: January 19, 2018)

quotesThe Keynote-224 is only a phase 2 study of good performance, very well selected HCC patients after sorafenib. But with a 16% response rate and 77% 6-month survival (median survival not yet reached), this is unprecedented good news for HCC patients. Median time on study was 8 months, which could amount to a very meaningful extension of life. The main question is whether these results will be seen with a more real-life patient population. But these data confirm what is seen with nivolumab and show a real benefit compared to other options in HCC (e.g regorafenib after sorafenib).quotes

Add Comment 1 Comment

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...